GP - It wouldn't surprise me to see announcements of one or two more studies for apabetalone targets funded by government arms or institutes over the next number of months. If this drug does half of what we think it could it has the potential to save healthcare systems worldwide hoards of money. The safety profile so far in BoM looks very good. If that is the first half of the battle then they are getting ready for the next surge.

tada